Lower circulating levels of myonectin were found in obese, type 2 diabetic patients and patients with glucose intolerance [76], while its increase was proposed as a biomarker for the development of diabetes mellitus [77] or as a marker of metabolic syndrome [78]. The gene discussed is ERFE; the disease is metabolic syndrome.